Cite
HARVARD Citation
Samuelsen, C. et al. (2020). Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States. Journal of medical economics. pp. 48-53. [Online].